Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines
- PMID: 10029595
- PMCID: PMC5550098
Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines
Abstract
Integrin-mediated adhesion influences cell survival and may prevent programmed cell death. Little is known about how drug-sensitive tumor cell lines survive initial exposures to cytotoxic drugs and eventually select for drug-resistant populations. Factors that allow for cell survival following acute cytotoxic drug exposure may differ from drug resistance mechanisms selected for by chronic drug exposure. We show here that drug-sensitive 8226 human myeloma cells, demonstrated to express both VLA-4 (alpha4beta1) and VLA-5 (alpha5beta1) integrin fibronectin (FN) receptors, are relatively resistant to the apoptotic effects of doxorubicin and melphalan when pre-adhered to FN and compared with cells grown in suspension. This cell adhesion mediated drug resistance, or CAM-DR, was not due to reduced drug accumulation or upregulation of anti-apoptotic Bcl-2 family members. As determined by flow cytometry, myeloma cell lines selected for drug resistance, with either doxorubicin or melphalan, overexpress VLA-4. Functional assays revealed a significant increase in alpha4-mediated cell adhesion in both drug-resistant variants compared with the drug-sensitive parent line. When removed from selection pressure, drug-resistant cell lines reverted to a drug sensitive and alpha4-low phenotype. Whether VLA-4-mediated FN adhesion offers a survival advantage over VLA-5-mediated adhesion remains to be determined. In conclusion, we have demonstrated that FN-mediated adhesion confers a survival advantage for myeloma cells acutely exposed to cytotoxic drugs by inhibiting drug-induced apoptosis. This finding may explain how some cells survive initial drug exposure and eventually express classical mechanisms of drug resistance such as MDR1 overexpression.
Figures







Similar articles
-
Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma.Oncogene. 2009 Jan 15;28(2):231-42. doi: 10.1038/onc.2008.385. Epub 2008 Oct 13. Oncogene. 2009. PMID: 18850009
-
Acquisition of resistance toward HYD1 correlates with a reduction in cleaved α4 integrin expression and a compromised CAM-DR phenotype.Mol Cancer Ther. 2011 Dec;10(12):2257-66. doi: 10.1158/1535-7163.MCT-11-0149. Epub 2011 Oct 6. Mol Cancer Ther. 2011. PMID: 21980133 Free PMC article.
-
Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model.Cancer Res. 2003 Nov 15;63(22):7900-6. Cancer Res. 2003. PMID: 14633719
-
Integrin-mediated drug resistance in multiple myeloma.Leuk Lymphoma. 2000 Jun;38(1-2):71-81. doi: 10.3109/10428190009060320. Leuk Lymphoma. 2000. PMID: 10811449 Review.
-
VLA-4-dependent myeloma cell adhesion.Leuk Lymphoma. 2001 Apr;41(3-4):239-45. doi: 10.3109/10428190109057979. Leuk Lymphoma. 2001. PMID: 11378537 Review.
Cited by
-
Very late antigen-4 (α(4)β(1) Integrin) targeted PET imaging of multiple myeloma.PLoS One. 2013;8(2):e55841. doi: 10.1371/journal.pone.0055841. Epub 2013 Feb 8. PLoS One. 2013. PMID: 23409060 Free PMC article.
-
The tumor microenvironment shapes hallmarks of mature B-cell malignancies.Oncogene. 2015 Sep 3;34(36):4673-82. doi: 10.1038/onc.2014.403. Epub 2015 Feb 2. Oncogene. 2015. PMID: 25639873 Free PMC article. Review.
-
Potent Activity of an Anti-ICAM1 Antibody-Drug Conjugate against Multiple Myeloma.Clin Cancer Res. 2020 Nov 15;26(22):6028-6038. doi: 10.1158/1078-0432.CCR-20-0400. Epub 2020 Sep 11. Clin Cancer Res. 2020. PMID: 32917735 Free PMC article.
-
CD84 mediates CLL-microenvironment interactions.Oncogene. 2017 Feb 2;36(5):628-638. doi: 10.1038/onc.2016.238. Epub 2016 Jul 25. Oncogene. 2017. PMID: 27452524
-
Bortezomib inhibits the survival and proliferation of bone marrow stromal cells.Blood Res. 2015 Jun;50(2):87-96. doi: 10.5045/br.2015.50.2.87. Epub 2015 Jun 25. Blood Res. 2015. PMID: 26157778 Free PMC article.
References
-
- Schustik C, Dalton WS, Gros P. Molecular Aspects of Medicine. Vol. 16. London, UK: Elsevier Science; 1995. P-glycoprotein–mediated multi-drug resistance in tumor cells: Biochemistry, clinical relevance and modulation; p. 1. - PubMed
-
- Dalton WS, Grogan TM, Rybski JA, Scheper RJ, Richter L, Kailey J, Broxterman HJ, Pinedo HM, Salmon SE. Immunohistochemical detection and quantification of P-glycoprotein in multiple drug-resistant human myeloma cells: Association with level of drug resistance and drug accumulation. Blood. 1989;73:747. - PubMed
-
- Durand RE, Sutherland RM. Effects of intercellular contact on repair of radiation damage. Exp Cell Res. 1972;71:75. - PubMed
-
- Teicher BA, Herman TS, Holden SA, Wang Y, Pfeffer MR, Crawford JW, Frei E., III Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science. 1990;247:1457. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous